Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2017 Publisher: EVER Neuro Pharma GmbH, Oberburgau 3, 4866 Unterach, Austria
Dacepton 5 mg/ml solution for infusion.
| Pharmaceutical Form |
|---|
|
Solution for infusion. Clear and colourless to slightly yellow solution, free from visible particles. pH of 3.3–4.0. Osmolality: 290 mOsm/kg |
1 ml contains 5 mg apomorphine hydrochloride hemihydrate.
20 ml contain 100 mg apomorphine hydrochloride hemihydrate.
Excipient with known effect:
Sodium metabisulphite (E223) 1 mg per ml.
Sodium chloride 8 mg per ml.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Apomorphine |
Apomorphine is a direct stimulant of dopamine receptors and while possessing both D1 and D2 receptor agonist properties does not share transport or metabolic pathways with levodopa. Its actions on parkinsonian motor disability are likely to be mediated at post-synaptic receptor sites. |
| List of Excipients |
|---|
|
Sodium metabisulphite (E223) |
Clear glass vials, type I with bromobutyl rubber stopper and a flip-off cap, containing 20 ml solution for infusion, in packs of 1, 5 or 30 vials.
Bundle packs: 5 × 1, 10 × 1, 30 × 1, 2 × 5 and 6 × 5.
Not all pack sizes may be marketed.
EVER Neuro Pharma GmbH, Oberburgau 3, 4866 Unterach, Austria
PL 40369/0003
20/2/2014
| Drug | Countries | |
|---|---|---|
| DACEPTON | Austria, Estonia, Spain, Finland, Ireland, Lithuania, Netherlands, Poland, Romania, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
